Table 2 Univariate and multivariate analysis of overall survival and recurrence-free survival in patients with renal cell carcinoma

Gender (male vs. female)

0.941

0.862

0.939

0.844

0.887

0.75

0.876

0.705

(0.474, 1.869)

(0.504, 1.752)

(0.422, 1.861)

(0.443, 1.734)

Age (≤60 vs. >60 years)

1.459

0.269

1.043

0.897

1.759

0.141

1.112

0.769

(0.747, 2.850)

(0.554, 1.961)

(0.829, 3.734)

(0.549, 2.251)

Tumor size (≤4 vs. 4–7 vs. >7cm)

1.399

0.145

1.448

0.083

1

0.999

0.898

0.715

(0.890, 2.198)

(0.953, 2.199)

(0.539, 1.854)

(0.503, 1.602)

Symptoms at diagnosis

1.951

0.05

1.605

0.126

2.35

0.04

1.745

0.121

(incidental vs. symptoms)

(1.001, 3.800)

(0.875, 2.942)

(1.038, 5.318)

(0.863, 3.527)

AJCC stage (T1 vs. T2 vs. T3-T4)

1.325

0.153

1.351

0.104

0.96

0.881

1.123

0.643

(0.901, 1.950)

(0.940, 1.942)

(0.565, 1.633)

(0.688, 1.831)

Lymph nodal status

1.079

0.725

1.097

0.637

0.997

0.989

0.962

0.861

(N0 vs. N1 vs. Nx)

(0.706, 1.649)

(0.746, 1.613)

(0.613, 1.620)

(0.620, 1.490)

Metastasis (M0 vs. M1)

3.389

0.023

4.324

0.003

5.109

0.014

6.807

0.001

(1.187, 9.677)

(1.642, 11.391)

(1.390, 18.787)

(2.103, 22.035)

Histologic variant

1.587

0.339

1.565

0.31

1.486

0.521

2.167

0.157

(clear cell vs. others)

(0.615, 4.091)

(0.659, 3.715)

(0.443, 4.981)

(0.734, 6.319)

Fuhrman’s grade

1.363

0.173

1.268

0.26

1.316

0.274

1.105

0.675

(1 vs. 2 vs. 3 vs. 4)

(0.873, 2.130)

(0.839, 1.918)

(0.805, 2.151)

(0.693, 1.761)

CXCR4 (low vs. high)

3.994

0.002

3.772

0.001

6.946

<0.001

8.034

<0.001

(1.655, 9.639)

(1.741, 8.169)

(2.498, 19.314)

(3.192, 20.221)

CXCR7 (low vs. high)

4.465

0.013

3.195

0.015

5.506

0.01

6.059

0.001

(1.366, 14.594)

(1.254, 8.139)

(1.506, 20.129)

(2.013, 18.237)

SDF-1 (low vs. high)

3.344

<0.001

3.206

<0.001

11.406

<0.001

14.025

<0.001

(1.713, 6.527)

(1.734, 5.928)

(4.718, 27.576)

(5.864,33.542)